TargetMol

AKN-028 trifluoroacetate

Product Code:
 
TAR-T29802
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T29802-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T29802-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T29802-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
AKN-028 trifluoroacetate induces cell cycle arrest, downregulation of Myc associated genes, and dose-dependent reduction of tyrosine kinase activity in acute myeloid leukemia.
CAS:
1175017-91-0
Formula:
C19H15F3N6O2
Molecular Weight:
416.364
Purity:
0.98
SMILES:
OC(=O)C(F)(F)F.Nc1ncc(nc1Nc1ccc2[nH]ccc2c1)-c1ccncc1

References

1. Eriksson A, Kalushkova A, Jarvius M, Hilhorst R, Rickardson L, Kultima HG, de Wijn R, Hovestad L, Frykn?s M, ?berg F, Larsson R, Parrow V, H?glund M. AKN-028 induces cell cycle arrest, downregulation of Myc associated genes and dose dependent reduction of tyrosine kinase activity in acute myeloid leukemia. Biochem Pharmacol. 2014 Jan 15;87(2):284-91. doi: 10.1016/j.bcp.2013.10.022. Epub 2013 Nov 4. PubMed PMID: 24200998. 2. Eriksson A, Hermanson M, Wickstr?m M, Lindhagen E, Ekholm C, Jenmalm Jensen A, L?thgren A, Lehmann F, Larsson R, Parrow V, H?glund M. The novel tyrosine kinase inhibitor AKN-028 has significant antileukemic activity in cell lines and primary cultures of acute myeloid leukemia. Blood Cancer J. 2012 Aug 3;2:e81. doi: 10.1038/bcj.2012.28. PubMed PMID: 22864397; PubMed Central PMCID: PMC3432483.